Natural Capsules Q2 Results 2026: Net loss ₹4 Cr, Revenue ₹51 Cr
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹51Cr
- Net profit
- −₹4Cr
- Margin
- 5.9%
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Natural Capsules Ltd Q2 FY27 key numbers
- Revenue
- Revenue from operations for the quarter ended 30th Sep 2026 (consolidated): Rs 5,115.28 lakhs.
As stated in Natural Capsules Ltd's Q2 FY27 results statement · published 14 Nov 2026. Reported figures, not investment advice.
Based on Natural Capsules Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended 30th Sep 2026 (consolidated): Rs 5,115.28 lakhs (Page 13). EBITDA (Q2 FY 2026): Rs 765.46 Lakhs, up 13.7% YoY from Rs 673.61 Lakhs.
From Natural Capsules Ltd's Q2 FY27 earnings-call transcript · updated 14 Nov 2026.
How did Natural Capsules' revenue grow in the September 2026 quarter?
- Revenue from operations for the quarter ended 30th Sep 2026 (consolidated): Rs 5,115.28 lakhs (Page 13).
- For the quarter ended 30th Sep 2025 (consolidated): Rs 4,580.27 lakhs (Page 13).
- Year-on-year revenue growth: Rs 5,115.28 lakhs vs Rs 4,580.27 lakhs, approx. 11.67% increase.
- Standalone revenue from operations for the quarter ended 30th Sep 2026: Rs 4,748.09 lakhs (Page 7).
What happened to Natural Capsules' margins in Q2 FY27?
EBITDA (Q2 FY 2026): Rs 765.46 Lakhs, up 13.7% YoY from Rs 673.61 Lakhs.
Locked: what Natural Capsules Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Natural Capsules planning?
2 more points from Natural Capsules Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Natural Capsules raising money or cutting debt?
The presentation on page 2 discloses a preferential issue of equity shares and convertible warrants:
Locked: what Natural Capsules Ltd said on fundraising
Also locked on this page: margins, order book
Free account, 30 seconds. No card needed.
How big is Natural Capsules' order book?
See what Natural Capsules Ltd said on order book & pipeline — free account, 30 seconds.
Natural Capsules Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.
Natural Capsules Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 51 |
| Operating profit (EBITDA) | 3 |
| Operating margin | 5.9% |
| Profit before tax | -5 |
| Net profit (PAT) | -4 |
| EPS (₹) | -4.08 |
Source: Natural Capsules Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹49 Cr, net loss ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Natural Capsules's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Sotac Pharmaceuticals (Q2 FY27)
7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how
- Bio Medica Lab (Q2 FY27)
EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —
- Syncom Formulations (India) (Q2 FY27)
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F
- Innova Captab (Q2 FY27)
Revenue from Operations for Q2 FY27 was ₹496.3 crore, a 30.5% year-on-year (YoY) increase from ₹380.4 crore in Q2 FY26 (Page 11). Key investor presentation take
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Natural Capsules Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Natural Capsules Ltd Q2 FY27 results?
Revenue from operations for the quarter ended 30th Sep 2026 (consolidated): Rs 5,115.28 lakhs (Page 13). EBITDA (Q2 FY 2026): Rs 765.46 Lakhs, up 13.7% YoY from Rs 673.61 Lakhs.
What is Natural Capsules Ltd share price analysis?
Natural Capsules Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹158 Cr. Investors should review the full earnings analysis for detailed insights.
Is Natural Capsules Ltd planning capital expenditure?
The results statement describes the following capex and expansion plans:.
Keep Natural Capsules Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.